Rwanda

Reimbursed Care Access

Rwanda permits limited medical use of ketamine in clinical settings (recently established private/tertiary hospital clinics) while most classical psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, mescaline, 2C‑X, ibogaine, ayahuasca) remain controlled under national narcotics/psychotropic legislation with no routine medical access outside approved research. National law vests the Minister of Health with authority to list and regulate narcotics/psychotropic substances and criminalizes unauthorized manufacture, possession and distribution, and public reporting indicates ketamine-based psychiatric services have been introduced at private hospitals but no publicly documented national reimbursement program for psychedelic therapies exists.